You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
THE 2-YEAR RESULTS OF ALIGN-AR TRIAL OF JENAVALVE Trilogy™ HEART VALVE SYSTEM WERE PRESENTED AT TCT2024
2024-11-01 16:59:18

At 2 years, the cardiac mortality rate was still lower than the study’s prespecified performance goal of 25% at 1 year, hemodynamics were excellent, rates of paravalvular leak were very low, and there were significant gains in quality of life. 

The release of these results indicates that JenaValve Trilogy™ is moving forward to benefit more patients! 

企业微信截图_20241115170040.png

For more information, please refer to TCT2024 conference website: https://www.tctmd.com/news/align-ar-2-yearsshows-promise-tavi-trilogy-aortic-regurgitation


Top